Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Impairment expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zomedica

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Its TRUFORMA biosensor platform is designed to assist practitioners in the diagnosis of complex conditions. The company was founded by Gerald L. Solensky. on January 7, 2013 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zomedica reports revenue growth and product advancements amidst profitability challenges

Zomedica's 2022 performance reflects revenue growth and product advancements, though challenges in profitability persist. The company's strategic focus on companion animal healthcare presents growth opportunities through innovation and market stability. Addressing expense management, stock stability, and leveraging market trends will be key for Zomedica's future success.

Zomedica reports robust Q1 earnings, eyes global equine market

Zomedica's Q1 2023 showcased strong revenue growth, particularly driven by TRUFORMA and international sales.
The company's focus on maintaining margins, expanding marketing efforts, and targeting global equine markets positions it for future success.
Challenges include the closure of the cancer assay program and operational hurdles in achieving the 70% gross margin target.
Opportunities lie in the launch of new assays, international expansion, and investor engagement beyond quarterly updates.

Zomedica reports robust Q2 earnings, eyes international expansion and product launches

Zomedica's Q2 performance reflects strong revenue growth and strategic investments for future profitability.
Despite challenges like increased OpEx and lower margins, the company is focused on long-term growth through product launches and market expansion.
Opportunities lie in international market exploration, upcoming product launches, and investor engagement strategies.

Zomedica reports record revenues, eyes global expansion amidst stock challenges

Zomedica's Q3 performance reflects strong revenue growth and strategic acquisitions, despite facing challenges like potential delisting and net losses.
The company's focus on new product launches, international expansion, and partnerships presents opportunities for future growth and market diversification.
Overall, Zomedica aims to drive towards cash flow breakeven by leveraging innovative products and maintaining a strong liquidity position.

Zomedica reports record revenues, eyes profitability through strategic growth

Zomedica's strong financial performance in Q4 2023 and full-year results, coupled with a robust cash position and strategic growth initiatives, position the company for future success.
While facing challenges related to compliance requirements and integration costs, Zomedica's focus on innovation, market expansion, and profitability goals present opportunities for sustained growth.
By balancing operational efficiency, product development, and financial discipline, Zomedica aims to drive revenue growth, enhance market presence, and deliver long-term value to shareholders.

Zomedica reports revenue growth and strong cash position in Q1

Zomedica's Q1 2024 performance showed revenue growth driven by key segments, strong cash position, and focus on operational efficiency. The company faces challenges in managing expenses and achieving aggressive revenue targets. Opportunities lie in expanding product lines, international sales, and maintaining financial strength.

Zomedica reports Q2 revenue growth amidst challenges and opportunities

Zomedica's Q2 performance showed revenue growth but with challenges in sales force and noncash charges.
Strengths include achieving milestones and expanding facilities, while opportunities lie in international expansion.
The company faces the task of managing cash burn and finding a new CFO.
Expectations for the second half of 2024 include revenue growth and operational focus.

Zomedica reports record Q3 revenue, eyes global expansion opportunities

Zomedica's Q3 2024 performance showcased revenue growth, margin strength, and cost reduction efforts, positioning the company for future profitability. Strategic international partnerships and product innovations underscore growth potential.
While challenges in achieving profitability persist, Zomedica's focus on operational efficiency and global expansion presents opportunities for sustained growth. Addressing investor inquiries and executing on strategic initiatives will be key to unlocking future value.
With a solid cash position, ongoing product enhancements, and expansion into new markets, Zomedica is poised for growth. Clear communication on financial targets, operational milestones, and strategic direction will be crucial for investor confidence and market success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ANN ARBOR, Mich., Aug.  03, 2020  (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (“Zomedica”) (NYSE American: ZOM) (TSX-V: ZOM), a veterinary health company, announced that Shameze Rampertab has resigned as Chief Financial Officer and member of the Board of Directors, effective August 14, 2020.

Zomedica Announces Management Change

Zomedica Pharmaceuticals Corp. (ZOM) closed at $0.16 in the latest trading session, marking a -0.3% move from the prior day.

Zomedica Pharmaceuticals Corp. (ZOM) Stock Sinks As Market Gains: What You Should Know

Permits Validation and Pilot Program Progress During COVID-19 Restrictions Permits Validation and Pilot Program Progress During COVID-19 Restrictions

Successful Remote Installation of TRUFORMA™

Zomedica Pharmaceuticals Corp. (ZOM) closed at $0.16 in the latest trading session, marking a +1.31% move from the prior day.

Zomedica Pharmaceuticals Corp. (ZOM) Outpaces Stock Market Gains: What You Should Know

ANN ARBOR, Mich., July  07, 2020  (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the closing of its previously announced public offering of 187,500,000 common shares (or common share equivalents) of the Company, together with warrants to purchase up to 187,500,000 common shares, at a combined public offering price of $0.16 per share and accompanying warrant.

Zomedica Pharmaceuticals Corp. Closes $30 Million Public Offering

iShares Nasdaq Biotechnology ETF

Zoom Video

The market might be facing turbulence, but Louis Navellier says there are three sectors that should treat investors well regardless   Do you know where the term “dog days of summer” comes from? I assumed it was some broad reference to the heat and humidity of high-summer that causes dogs to lie around doing nothing.

Stocks to Buy for the “Dog Days” of Summer

ANN ARBOR, Mich., July  01, 2020  (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the pricing of its previously announced public offering of 187,500,000 common shares (or common share equivalents) of the Company, together with short-term warrants to purchase up to 187,500,000 common shares, at a combined public offering price of $0.16 per share and accompanying warrant. Each common share (or common share equivalent) is being sold in the offering together with one two-year warrant to purchase one common share at an exercise price of $0.16 per common share. There is no public trading market for the warrants, and Zomedica does not expect a market to develop.

Zomedica Pharmaceuticals Corp. Announces $30 Million Public Offering

ANN ARBOR, Mich., July  01, 2020  (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary diagnostic company, announced today that it has commenced a public offering of its common shares, together with warrants to purchase its common shares. All of the common shares and warrants in the offering will be sold by Zomedica. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. 

Zomedica Pharmaceuticals Corp. Announces Proposed Public Offering

Zomedica (ZOM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Zomedica (ZOM) in Focus: Stock Moves 7.2% Higher

Moves Closer to Development Completion of Its Novel Point-of-Care Diagnostic Platform Moves Closer to Development Completion of Its Novel Point-of-Care Diagnostic Platform

Zomedica Appoints New Interim CEO to Lead Organization Through Inaugural Product Launch

ANN ARBOR, Mich., May  29, 2020  (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the closing of its previously announced public offering of 133,333,333 common shares (or common share equivalents) of the Company, together with warrants to purchase up to 133,333,333 common shares, at a combined public offering price of $0.15 per share and accompanying warrant.

Zomedica Pharmaceuticals Corp. Closes $20 Million Public Offering

ANN ARBOR, Mich., May  26, 2020  (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the pricing of a public offering of 133,333,333 common shares (or common share equivalents) of the Company, together with warrants to purchase up to 133,333,333 common shares, at a combined public offering price of $0.15 per share and accompanying warrant. Each common share (or common share equivalent) is being sold in the offering together with one two-year warrant to purchase one common share at an exercise price of $0.15 per common share. There is no established public trading market for the warrants, and Zomedica does not expect a market to develop.

Zomedica Pharmaceuticals Corp. Announces $20 Million Public Offering

Canine TSH, Feline TSH and Feline total T4 added to Canine total T4 Canine TSH, Feline TSH and Feline total T4 added to Canine total T4

Zomedica Completes Verification of Three More Assays for its TRUFORMA™ Point-of-Care Diagnostic Platform

Zomedica Pharmaceuticals Corp (ZOM) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zomedica Pharmaceuticals Corp (ZOM) Reports Q1 Loss, Lags Revenue Estimates

Meets Major Development Milestone with Qorvo Meets Major Development Milestone with Qorvo

Zomedica Completes Verification of its TRUFORMA™ Point-of-Care Diagnostic Platform and the First Assay, Canine total T4

ANN ARBOR, Mich., April  07, 2020  (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the pricing of its previously announced public offering of 33,333,334 common shares and warrants to purchase up to 16,666,667 common shares. The securities are being sold in a fixed combination consisting of one common share and 0.5 of a warrant at a combined public offering price of $0.12 per share and accompanying warrant. Each whole warrant will be exercisable for one common share. The gross proceeds to Zomedica from this offering are expected to be approximately $4.0 million, before deducting placement agent fees and other estimated offering expenses, and excluding the exercise of any warrants. All of the common shares and warrants in the offering will be sold by Zomedica. The offering is expected to close on or about April 9, 2020, subject to satisfaction of customary closing conditions.

Zomedica Pharmaceuticals Corp. Announces Pricing of $4.0 Million Public Offering

ANN ARBOR, Mich., April  07, 2020  (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced that it has commenced a public offering of its common shares and warrants to purchase common shares. All of the common shares and warrants in the offering will be sold by Zomedica. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Zomedica Pharmaceuticals Corp. Announces Public Offering

ANN ARBOR, Mich., Feb.  14, 2020  (GLOBE NEWSWIRE) --  Zomedica Pharmaceuticals Corp.  (NYSE American: ZOM)(“Zomedica” or “Company”), a veterinary diagnostic company, announced today the completion of its previously announced registered direct offering of 20,833,334 of its common shares at a purchase price of $0.12 per share, for gross proceeds of $2.5 million.

Zomedica Announces Completion of $2.5 Million Registered Direct Offering

ANN ARBOR, Mich., Feb.  12, 2020  (GLOBE NEWSWIRE) --  Zomedica Pharmaceuticals Corp.  (NYSE American: ZOM) (“Zomedica” or “Company”), a veterinary diagnostic company, announced today that it has entered into a definitive agreement with institutional investors for the issuance and sale in a registered direct offering of 20,833,334 of its common shares at a purchase price of $0.12 per share, for gross proceeds of $2.5 million. The offering is expected to close on or about February 14, 2020, subject to the satisfaction of customary closing conditions.

Zomedica Announces $2.5 Million Registered Direct Offering

Common Shares will continue to be listed on the NYSE American Common Shares will continue to be listed on the NYSE American

Zomedica to Voluntarily Delist its Common Shares from TSX Venture Exchange Effective February 10, 2020

Strategic Plan to Emphasize Point-of-Care Diagnostics Strategic Plan to Emphasize Point-of-Care Diagnostics

Zomedica to Focus on TRUFORMA™ Commercialization

Intends to Seek Commercialization Partner for Platform Intends to Seek Commercialization Partner for Platform

Zomedica Successfully Completes Development and Manufacturing Milestones for its Cancer Liquid Biopsy Platform

Repositioning for Next Stage of Growth Repositioning for Next Stage of Growth

Zomedica Announces Management Changes

Large Pennsylvania referral clinic added to University of Georgia Large Pennsylvania referral clinic added to University of Georgia

Zomedica Expands ZM-006 Pilot Efficacy Study

ANN ARBOR, Mich., Nov.  05, 2019  (GLOBE NEWSWIRE) --  Zomedica Pharmaceuticals Corp.  (TSX-V:ZOM) (“Zomedica” or “Company”), a veterinary pharmaceutical and health care solutions company, is pleased to announce that all ordinary and special resolutions were passed at the Annual and Special Meeting of Shareholders, which was held today in Toronto, Ontario, Canada. An aggregate of 69,531,652 shares (64.4%) of all issued and outstanding shares of the Company were represented at the meeting in person or by proxy. The following six nominees were re-elected as Directors of the Company to serve until the next annual meeting of shareholders of the Company, or until their successors are elected or appointed: Gerald Solensky Jr., Shameze Rampertab, Jeffrey Rowe, James LeBar, Rodney Williams, and Johnny D. Powers. 

News for Zomedica Stock (ZOM)